Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9213508 | 0.98 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL11236829 | 0.98 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL6839659 | 0.98 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL61669 | 0.98 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL7459531 | 0.98 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL60610 | 0.98 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL11236833 | 0.98 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL28861193 | 0.98 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL11236830 | 0.98 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL25337874 | 0.96 | ALDH1A1 (0.45) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398831-B1 | AQUEOUS POLYMER DISPERSION MADE OF A VINYLAROMATIC COMPOUND, CONJUGATED ALIPHATIC DIENE, AND ETHYLENICALLY UNSATURATED ACID | BASF SE (DE) | 2013-05-29 | — | — | EP | claimed |
| US-20110281130-A1 | AQUEOUS POLYMER DISPERSION OBTAINED FROM A VINYLAROMATIC COMPOUND, CONJUGATED ALIPHATIC DIENE AND ETHYLENICALLY UNSATURATED ACID | BASF SE (DE) | 2011-11-17 | — | — | US | claimed |
| US-12018001-B2 | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3802499-B1 | PYRIMIDINE CYCLOHEXENYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024068674-A1 | NUCLEIC ACID COMPLEXES AND USES THEREOF | BioNTech SE (DE) | 2024-04-04 | — | — | WO | disclosed |
| US-11945808-B2 | Substituted cyclohexyl compounds as NOP inhibitors | DART NEUROSCIENCE, LLC (US) | 2024-04-02 | — | — | US | disclosed |
| US-11932601-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-112236416-B | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | 科赛普特治疗公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023148277-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY OF NUCLEIC ACIDS TO CELLS | BioNTech SE (DE) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023148276-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | BioNTech SE (DE) | 2023-08-10 | — | — | WO | disclosed |
| US-20230183186-A1 | PYRIMIDINE CYCLOHEXENYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INCORPORATED | 2023-06-15 | — | — | US | disclosed |
| US-4847429-A | ALKYLATION, ACID CATALYSTS, DEHYDROGENATION | EASTMAN KODAK COMPANY (US) | 1989-07-11 | — | — | US | disclosed |
| WO-1989000987-A1 | PROCESS FOR PRODUCING PHENYLHYDROQUINONES | EASTMAN KODAK COMPANY (US) | 1989-02-09 | — | — | WO | disclosed |
| US-4317932-A | Preparation of secondary amines | W. R. GRACE & CO. (US) | 1982-03-02 | — | — | US | disclosed |
| US-4252707-A | AMINE SALT, WATER-THINNABLE | RUID JOHN O | 1981-02-24 | — | — | US | disclosed |
| US-4250964-A | INJECTING CYCLOHEXENE OR CYCLOHEXADIENE TO REDUCE VISCOSITY | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1981-02-17 | — | — | US | disclosed |
| US-3945837-A | RESINOUS BINDER, HYDROCARBON SOLVENT, MODIFIED DYE | SAKURA COLOR PRODUCTS CORPORATION (JA) | 1976-03-23 | — | — | US | disclosed |
| US-3929677-A | Perfume compositions and perfurme articles containing one isomer of an octahydrotetramethyl acetonaphthone | INT FLAVORS & FRAGRANCES INC | 1975-12-30 | — | — | US | disclosed |
| US-3911018-A | Novel process and products produced by said process | INT FLAVORS & FRAGRANCES INC | 1975-10-07 | — | — | US | disclosed |
| US-3907321-A | Novel tobacco product comprising one or more isomers of an octahydrotetramethyl acetonaphthone | INT FLAVORS & FRAGRANCES INC | 1975-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945808-B2 | Substituted cyclohexyl compounds as NOP inhibitors | OPRL1, OPRK1, NOP56 | ALDH1A1 2958/4885ALOX15 3104/4885PKM 2911/4885 |
| US-20230183186-A1 | PYRIMIDINE CYCLOHEXENYL GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, MC2R | ALDH1A1 3630/4885ALOX15 1388/4885PKM 3323/4885 |
| US-11932601-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | ALDH1A1 219/4885ALOX15 101/4885PKM 3394/4885 |
| US-12018001-B2 | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | ALDH1A1 3551/4885ALOX15 1198/4885PKM 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.